Cellectar Biosciences (CLRB) Expected to Announce Quarterly Earnings on Wednesday

Cellectar Biosciences (NASDAQ:CLRB) is projected to release its Q4 2025 results before the market opens on Wednesday, March 4th. Analysts expect Cellectar Biosciences to post earnings of ($1.20) per share for the quarter. Investors may visit the the company’s upcoming Q4 2025 earning results page for the latest details on the call scheduled for Wednesday, March 4, 2026 at 8:30 AM ET.

Cellectar Biosciences Price Performance

Cellectar Biosciences stock traded down $0.03 during midday trading on Thursday, hitting $3.45. 7,310 shares of the company’s stock were exchanged, compared to its average volume of 76,761. Cellectar Biosciences has a 52-week low of $2.45 and a 52-week high of $20.60. The stock has a 50-day moving average price of $3.24 and a two-hundred day moving average price of $3.92. The company has a debt-to-equity ratio of 0.04, a quick ratio of 2.77 and a current ratio of 2.77. The company has a market cap of $14.62 million, a P/E ratio of -0.38 and a beta of 0.32.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Cellectar Biosciences in a research report on Wednesday, January 21st. One analyst has rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Hold”.

Institutional Trading of Cellectar Biosciences

Hedge funds and other institutional investors have recently bought and sold shares of the company. Bank of America Corp DE grew its position in Cellectar Biosciences by 25.3% during the fourth quarter. Bank of America Corp DE now owns 206,783 shares of the biopharmaceutical company’s stock valued at $62,000 after acquiring an additional 41,704 shares during the last quarter. DRW Securities LLC lifted its holdings in shares of Cellectar Biosciences by 114.2% in the 4th quarter. DRW Securities LLC now owns 45,190 shares of the biopharmaceutical company’s stock worth $133,000 after acquiring an additional 24,089 shares during the last quarter. Citadel Advisors LLC purchased a new stake in shares of Cellectar Biosciences in the 3rd quarter valued at $104,000. Dimensional Fund Advisors LP bought a new position in shares of Cellectar Biosciences during the 3rd quarter valued at $73,000. Finally, XTX Topco Ltd bought a new position in shares of Cellectar Biosciences during the 4th quarter valued at $36,000. Hedge funds and other institutional investors own 16.41% of the company’s stock.

Cellectar Biosciences Company Profile

Cellectar Biosciences, Inc is a clinical‐stage biopharmaceutical company focused on the development of targeted cancer therapies and imaging agents. The company’s proprietary phospholipid drug conjugate (PDC) technology platform is designed to selectively deliver therapeutic and diagnostic payloads to malignant cells while sparing healthy tissue. Through its PDC approach, Cellectar aims to improve the efficacy and safety profile of traditional treatments like chemotherapy and radiotherapy.

Its lead therapeutic candidate, CLR 131, is a radioisotope‐labeled PDC being evaluated in Phase II clinical trials for relapsed or refractory B‐cell malignancies, including multiple myeloma and non‐Hodgkin lymphoma.